ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs MXN
20.7918
0.00%
Brent Oil
80.005
0.00%
Bitcoin
103,284.43
-0.81%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX

  6. Channel Therapeutics Corporation (CHRO) Cotización

Channel Therapeutics Corporation

Channel Therapeutics Corporation (CHRO)

AMEX
1.90
0.94
(97.92%)
Cerrado 17 Enero 3:00PM
Delayed by 15 minutes
2.06
0.16
(8.42%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
2.06
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
14,269,760
1.00 Rango del Día 2.45
0.45 Rango de 52 semanas 6.00
Capitalización de Mercado [m]
12.418M
Precio Anterior
0.96
Precio de Apertura
1.09
Hora
351
@
2.06
(formt)
Última hora de negociación
Volumen financiero
US$ 24,062,359
Precio Promedio Ponderado
1.6862
Volumen promedio (3 m)
109,880
Acciones en circulación
6,028,011
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.55
Beneficio por acción (BPA)
-1.22
turnover
-
Beneficio neto
-7.38M

Acerca de Channel Therapeutics Corporation

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. I... Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
channeltherapeutics.com
Sede
Reno, Nevada, USA
Fundado
-
Channel Therapeutics Corporation is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CHRO. The last closing price for Channel Therapeutics was US$0.96. Over the last year, Channel Therapeutics shares have traded in a share price range of US$ 0.45 to US$ 6.00.

Channel Therapeutics currently has 6,028,011 shares in issue. The market capitalisation of Channel Therapeutics is US$5.79 million. Channel Therapeutics has a price to earnings ratio (PE ratio) of -1.55.

CHRO Últimas noticias

Más noticias

Chromocell Announces Amendment to Stock Repurchase Plan

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

24 Octubre 2024
GlobeNewswire Inc.

Chromocell to Participate in the Virtual Investor Lunch Break Series

FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

15 Julio 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

18 Junio 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

15 Mayo 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

15 Mayo 2024
Edgar (US Regulatory)

Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024

FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

13 Mayo 2024
GlobeNewswire Inc.

Chromocell Issues Letter to Stockholders from Chief Executive Officer

FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

09 Abril 2024
GlobeNewswire Inc.

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

21 Marzo 2024
GlobeNewswire Inc.

Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

18 Marzo 2024
GlobeNewswire Inc.

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...

11 Marzo 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
11.05103.960396041.012.060.811640490.9484076CS
41.414218.8854489160.6462.060.5621159630.8437335CS
121.339185.7142857140.7212.060.451098800.73445435CS
260.8976.06837606841.172.060.451121050.79697305CS
52-3.94-65.6666666667660.45726061.03918864CS
156-3.94-65.6666666667660.45726061.03918864CS
260-3.94-65.6666666667660.45726061.03918864CS

CHRO - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Channel Therapeutics?
El precio actual de las acciones de Channel Therapeutics es US$ 2.06
¿Cuántas acciones de Channel Therapeutics están en circulación?
Channel Therapeutics tiene 6,028,011 acciones en circulación
¿Cuál es la capitalización de mercado de Channel Therapeutics?
La capitalización de mercado de Channel Therapeutics es USD 5.79M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Channel Therapeutics?
Channel Therapeutics ha negociado en un rango de US$ 0.45 a US$ 6.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Channel Therapeutics?
El ratio precio/beneficio de Channel Therapeutics es -1.55
¿Cuál es la moneda de reporte de Channel Therapeutics?
Channel Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Channel Therapeutics?
El último beneficio anual de Channel Therapeutics es USD -7.38M
¿Cuál es la dirección registrada de Channel Therapeutics?
La dirección registrada de Channel Therapeutics es 50 WEST LIBERTY STREET, SUITE 880, RENO, NEVADA, 89501
¿Cuál es la dirección del sitio web de Channel Therapeutics?
La dirección del sitio web de Channel Therapeutics es channeltherapeutics.com
¿En qué sector industrial opera Channel Therapeutics?
Channel Therapeutics opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CHROChannel Therapeutics Corporation
US$ 1.90
(97.92%)
14.26M
GPUSHyperscale Data Inc
US$ 4.60
(22.99%)
215.83k
VINEFresh Vine Wine Inc
US$ 0.6899
(22.98%)
376.38k
RHERegional Health Properties Inc
US$ 2.40
(18.81%)
225.06k
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 13.245
(16.80%)
62.42M
FOXOFOXO Technologies Inc
US$ 0.2295
(-27.14%)
11.33M
OSTXOS Therapies Incorporated
US$ 3.03
(-26.46%)
1.63M
AEONAEON Biopharma Inc
US$ 0.1401
(-18.02%)
29.84M
MSTZT Rex 2X Inverse MSTR Daily Target ETF
US$ 12.56
(-16.32%)
26.29M
BOILProShares Ultra Bloomberg Natural Gas New
US$ 67.43
(-14.52%)
3.87M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 32.49
(8.34%)
69.68M
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 13.245
(16.80%)
62.44M
FXIiShares China Large Cap
US$ 30.40
(1.91%)
59.69M
SPYSPDR S&P 500
US$ 597.58
(1.00%)
57.16M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
US$ 18.33
(-8.03%)
53.84M

Discusión

Ver feed completo
Slaytanic420 Slaytanic420 7 minutos hace
Delusional hmbl pumpers on x stock twits and x
HMBL
eskayes eskayes 7 minutos hace
That is beautiful
TGLO
GUNSMOKE GUNSMOKE 8 minutos hace
https://youtu.be/P96KFQQSeoE
UMAV
Eli's Gone Eli's Gone 11 minutos hace
I remember when Conseco broke the $5M barrier---bunch of us guys were having a beer after work---we were all at or around $50K/yr...so we started BS'in about how the $5M would equate in our world...I said just take 2 zeroes off all your current stuff while keeping your current salary---a $100 dinner
Value_Investor Value_Investor 12 minutos hace
Buying FCCN at today's high $9.9 = buying FRCN at $1.2881 which is 537 Times of its recent high $0.0024!

Buying FCCN at its record high $41.3 = buying FRCN at $5.3735 v.s. its record high was $8.6 !

https://api.wsj.net/api/kaavio/charts/big.chart?nosettings=1&s
FCCN FRCN
GUNSMOKE GUNSMOKE 15 minutos hace
UMAC !! BREAK THE FLAG GOIRGIE DREW FCUK-IT !!
UMAC
janice shell janice shell 15 minutos hace
Very nasty.
PickStocks PickStocks 16 minutos hace
Yes....this will be a monster
COOP
RickNagra RickNagra 16 minutos hace
Great video. Thanks for sharing.
FNMA
Monroe1 Monroe1 16 minutos hace
I do love my long weekends especially this one... so many good things on the horizon for CytoDyn especially with the changes coming to our health care system.
So Univ of Missouri? Or Icahn School of Medicine?

I nominate Senator Rory Blunt for a Director's seat on the CytoDyn
CYDY
radly radly 18 minutos hace
0.000001
Enough said
UBQU
OnlyCredibleFactsMatter OnlyCredibleFactsMatter 19 minutos hace
Way to stay on topic highlighting SRMX, Tricascade products.

Hats off to CanItBe for doing an excellent job with finding and posting the latest news and useful information about SRMX.
SRMX
noradio noradio 19 minutos hace
Hoe likely is it that all bashers stopped posting after 11am today?
DBMM
KILLAZILLA KILLAZILLA 19 minutos hace
Quite certain EVERY person that signed the Declaration of independence WAS a "CRITIC"...

SILLY MAMALUKE!!!
WDLF
daleb2130 daleb2130 20 minutos hace
Gensler  was evil 
MSMY
rbtree rbtree 21 minutos hace
[ittle over 500k shares @ .000001

Such a winner you are.. well, if that garbage ever got to .0006, you'd have a whopping $295 in profits...
NNRX
fuagf fuagf 22 minutos hace
Lucky for California Trump wasn't in - Jan 15, 2025 - California secures expanded federal funding to repair firestorm-damaged public infrastructure

What you need to know: Governor Gavin Newsom today announced federal assistance for local governments to repair or replace public facilit
EternalPatience EternalPatience 22 minutos hace
Waiting to see the egg on your face soon. Please do show up. Don't run away
FNMA
bar1080 bar1080 22 minutos hace
Sometimes I felt sorry for Lorsch. I remember a video of a Thalian party where he sat off by himself, away from Kira, ignored by all the has-been show biz types. He seemed to have health problems, didn't dance, ... was probably out of options by then. That was near the end.
Hi_Lo Hi_Lo 22 minutos hace
There is a huge change of leadership going on right now.
Really?

Where is Jake P. Noch's lawsuit he said he would file to get the books from the TA?

It doesn't exist. And even if he does file he has to win. There could be solid legal reasons the TA won't hand o
BCAP
dinogreeves dinogreeves 25 minutos hace
For all of you chart readers on this board. Do you see this happening in 2 months.


https://investorshub.advfn.com/uimage/uploads/2025/1/17/stwjv9B861898-0F27-42BC-9451-689AA07166A8.webp
SMCI
GUNSMOKE GUNSMOKE 26 minutos hace
UMAV !! ITS ALL GOOD IM ON FREE SHARES ! Your bad -ass an i know-it !!
UMAV
Investor082 Investor082 26 minutos hace
Sounds good. We will track the progress towards $90M revenue every quarter. No more BS saying but I said 600 patients! ;)
NWBO
Involuntary-Recluse Involuntary-Recluse 26 minutos hace
Markets require buyers and sellers my good man.

The Gekko's that flipped DCDG (HMBL predecessor) from .0001--------.0003 looked brilliant when it hit $5.00 ;-)😂 😂

The BIGGER moves come right after the BIG moves, but it takes chutzpah to hold onto a winn
HMBL
Hi_Lo Hi_Lo 27 minutos hace
Lying pumpers like the one you are responding to love lying fraudsters like themselves.

They are thick as thieves.
BCAP

Su Consulta Reciente

AMEX
CHRO
Channel Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados